Flexion Therapeutics (FLXN) Announces Prelim. Q4 and FY Results and FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020
January 9, 2020 4:01 PM ESTFourth-quarter 2019 revenue estimated to be approximately $23.7 millionFull-year 2019 revenue estimated to be approximately $73 million, representing year-over-year growth of more than 220%Flexion provides 2020 product revenue guidance of $120 million to $135 million
BURLINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced preliminary and unaudited revenue for the fourth-quarter and full-year ended December 31, 2019 and provided initial revenue guidance for 2020.
We are very pleased with ZILRETTAs performance in the... More
